StockNews.com Downgrades Dynavax Technologies (NASDAQ:DVAX) to Hold

StockNews.com lowered shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a research note issued to investors on Friday morning.

DVAX has been the topic of several other reports. William Blair reiterated an outperform rating on shares of Dynavax Technologies in a report on Friday, February 23rd. The Goldman Sachs Group started coverage on shares of Dynavax Technologies in a research note on Thursday, February 1st. They set a neutral rating and a $20.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $25.00.

Dynavax Technologies Stock Up 1.2 %

Shares of DVAX opened at $11.34 on Friday. The firm has a fifty day moving average price of $12.20 and a 200-day moving average price of $13.15. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $1.48 billion, a P/E ratio of -188.97 and a beta of 1.26. Dynavax Technologies has a 12-month low of $10.06 and a 12-month high of $15.15.

Insider Activity at Dynavax Technologies

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $12.78, for a total value of $262,322.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.98% of the company’s stock.

Institutional Trading of Dynavax Technologies

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BluePath Capital Management LLC purchased a new stake in shares of Dynavax Technologies in the 3rd quarter valued at $33,000. DekaBank Deutsche Girozentrale purchased a new stake in Dynavax Technologies during the third quarter worth about $33,000. Advisor Resource Council acquired a new stake in shares of Dynavax Technologies during the fourth quarter worth about $144,000. Rathbones Group PLC purchased a new position in shares of Dynavax Technologies in the third quarter valued at approximately $158,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Dynavax Technologies in the fourth quarter valued at approximately $209,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.